ASSOCIATION OF INSULIN PUMP THERAPY WITH RAISED SERUM AMYLOID A IN TYPE I DIABETES MELLITUS

Michael Brownlee; Anthony Cerami; Jenny J. Li; Helen Vlassara; Terry R. Martin; Keith P.W.J. Mcadam

doi:10.1016/S0140-6736(84)91750-1

ASSOCIATION OF INSULIN PUMP THERAPY WITH RAISED SERUM AMYLOID A IN TYPE I DIABETES MELLITUS

Michael Brownlee, Anthony Cerami, Jenny J. Li, Helen Vlassara, Terry R. Martin, Keith P.W.J. Mcadam

Medicine

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Serum concentrations of serum amyloid A protein, the high-density-lipoprotein-associated tissue amyloid A precursor, were determined in 29 diabetic patients receiving insulin by subcutaneous injection and in 50 receiving subcutaneous infusion pump therapy. Insulin delivered by continuous subcutaneous pumps stimulated serum amyloid A production to levels nearly six times those in normal subjects, nearly twice as much as insulin given by subcutaneous injection. 85% of patients with serum amyloid A levels {succeeds or equal to}10⁴ ng/ml were being treated with insulin pump therapy. The relation between insulin aggregation and amyloid A in diabetes was evaluated in 1 patient; treatment with syringe-aggregated insulin resulted in a nearly 300% increase in serum amyloid A levels. The use of high-potency non-aggregating insulins in the pump treatment of type I diabetic patients may be necessary for optimum therapy.

Original language	English (US)
Pages (from-to)	411-413
Number of pages	3
Journal	The Lancet
Volume	323
Issue number	8374
DOIs	https://doi.org/10.1016/S0140-6736(84)91750-1
State	Published - Feb 25 1984

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(84)91750-1

Cite this

@article{0095c9ef9183450c9b135af606102785,

title = "ASSOCIATION OF INSULIN PUMP THERAPY WITH RAISED SERUM AMYLOID A IN TYPE I DIABETES MELLITUS",

abstract = "Serum concentrations of serum amyloid A protein, the high-density-lipoprotein-associated tissue amyloid A precursor, were determined in 29 diabetic patients receiving insulin by subcutaneous injection and in 50 receiving subcutaneous infusion pump therapy. Insulin delivered by continuous subcutaneous pumps stimulated serum amyloid A production to levels nearly six times those in normal subjects, nearly twice as much as insulin given by subcutaneous injection. 85% of patients with serum amyloid A levels {succeeds or equal to}104 ng/ml were being treated with insulin pump therapy. The relation between insulin aggregation and amyloid A in diabetes was evaluated in 1 patient; treatment with syringe-aggregated insulin resulted in a nearly 300% increase in serum amyloid A levels. The use of high-potency non-aggregating insulins in the pump treatment of type I diabetic patients may be necessary for optimum therapy.",

author = "Michael Brownlee and Anthony Cerami and Li, {Jenny J.} and Helen Vlassara and Martin, {Terry R.} and Mcadam, {Keith P.W.J.}",

note = "Funding Information: We thank Dr Edward Condon, Dr Howard Kolodny, Dr M. A. Charles, and Dr Bernard Robms, for helping us to acquire patient material for this study; and Ms Alice Striegel for secretarial assistance. This work was partly supported by a gift from Mr Ralph Covelli. M. B. is the recipient of Public Health Service Special Emphasis Research Career Award (1-KOlAM00589-01) from National Institute of Arthritis, Metabolism and Digestive Diseases and National Heart, Lung and Blood Institute. H. V. is the recipient of Research Scientist Development Award (1-KOI-AGO0148-01) from NIAMDD and National Institute of Aging. be addressed to M. B., Laboratory of Medical University, 1230 York Avenue, New York, NY",

year = "1984",

month = feb,

day = "25",

doi = "10.1016/S0140-6736(84)91750-1",

language = "English (US)",

volume = "323",

pages = "411--413",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8374",

}

TY - JOUR

T1 - ASSOCIATION OF INSULIN PUMP THERAPY WITH RAISED SERUM AMYLOID A IN TYPE I DIABETES MELLITUS

AU - Brownlee, Michael

AU - Cerami, Anthony

AU - Li, Jenny J.

AU - Vlassara, Helen

AU - Martin, Terry R.

AU - Mcadam, Keith P.W.J.

N1 - Funding Information: We thank Dr Edward Condon, Dr Howard Kolodny, Dr M. A. Charles, and Dr Bernard Robms, for helping us to acquire patient material for this study; and Ms Alice Striegel for secretarial assistance. This work was partly supported by a gift from Mr Ralph Covelli. M. B. is the recipient of Public Health Service Special Emphasis Research Career Award (1-KOlAM00589-01) from National Institute of Arthritis, Metabolism and Digestive Diseases and National Heart, Lung and Blood Institute. H. V. is the recipient of Research Scientist Development Award (1-KOI-AGO0148-01) from NIAMDD and National Institute of Aging. be addressed to M. B., Laboratory of Medical University, 1230 York Avenue, New York, NY

PY - 1984/2/25

Y1 - 1984/2/25

N2 - Serum concentrations of serum amyloid A protein, the high-density-lipoprotein-associated tissue amyloid A precursor, were determined in 29 diabetic patients receiving insulin by subcutaneous injection and in 50 receiving subcutaneous infusion pump therapy. Insulin delivered by continuous subcutaneous pumps stimulated serum amyloid A production to levels nearly six times those in normal subjects, nearly twice as much as insulin given by subcutaneous injection. 85% of patients with serum amyloid A levels {succeeds or equal to}104 ng/ml were being treated with insulin pump therapy. The relation between insulin aggregation and amyloid A in diabetes was evaluated in 1 patient; treatment with syringe-aggregated insulin resulted in a nearly 300% increase in serum amyloid A levels. The use of high-potency non-aggregating insulins in the pump treatment of type I diabetic patients may be necessary for optimum therapy.

AB - Serum concentrations of serum amyloid A protein, the high-density-lipoprotein-associated tissue amyloid A precursor, were determined in 29 diabetic patients receiving insulin by subcutaneous injection and in 50 receiving subcutaneous infusion pump therapy. Insulin delivered by continuous subcutaneous pumps stimulated serum amyloid A production to levels nearly six times those in normal subjects, nearly twice as much as insulin given by subcutaneous injection. 85% of patients with serum amyloid A levels {succeeds or equal to}104 ng/ml were being treated with insulin pump therapy. The relation between insulin aggregation and amyloid A in diabetes was evaluated in 1 patient; treatment with syringe-aggregated insulin resulted in a nearly 300% increase in serum amyloid A levels. The use of high-potency non-aggregating insulins in the pump treatment of type I diabetic patients may be necessary for optimum therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021351442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021351442&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(84)91750-1

DO - 10.1016/S0140-6736(84)91750-1

M3 - Article

C2 - 6142148

AN - SCOPUS:0021351442

SN - 0140-6736

VL - 323

SP - 411

EP - 413

JO - The Lancet

JF - The Lancet

IS - 8374

ER -

ASSOCIATION OF INSULIN PUMP THERAPY WITH RAISED SERUM AMYLOID A IN TYPE I DIABETES MELLITUS

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this